New nebulizer technology

Drug Delivery to the Lung

Volumn , Issue , 2001, Pages 303-336

  Dennis, John H ^a   Nerbrink, Ola ^b  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84971591572     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (35)

1. Nikander K. Some technical, physicochemical and physiological aspects of nebulization of drugs. Eur Respir J 1997; 7(44): 168–172.
2. Dennis JH, Hendrick DJ. Design characteristics for drug nebulizers. J Med Eng Technol 1992; 16(2):63–68.
3. Smye SW. The physics of corticosteroid nebulization. Eur Respir J 1997; 7(44):184–188.
4. Geddes DM. Nebulized therapy and cystic fibrosis. Eur Respir J 1997; 7(44):173–176.
5. Muers MF. The rational use of nebulizers in clinical practice. Eur Respir J 1997; 7(44):189–197. 1997.
6. Dennis JH, Stenton SC, Beach JR, Avery AJ, Walters EH, Hendrick DJ. Jet and ultrasonic nebulizer output: use of a new method to measure aerosol output directly. Thorax 1990; 45:728–732.
7. Dennis JH. Drug nebulizer design and performance: breath-enhanced jet vs constant output jet vs ultrasonic. J Aerosol Med 1995; 8(3):277–280.
8. Pavia D, McLeod L. The environmental impact of inhaled aerosols. Eur Respir Rev 1994; 4(suppl 18):75–77.
9. Denyer J, Dyche A, Nikander K, Newman S, Richards J, Dean A. HaloLite A novel liquid drug aerosol delivery system. Thorax 1997; 52(6):A83.
10. Denyer J, Dyche A. Patient compliance with inhaled treatment using a novel aerosol delivery system. Eur Respir J 1998; 12(S28):P0647.
11. HaloLite: Anovel liquid drug aerosol delivery system. J. Denyer, K. Nikander. RDD VI May 1998.
12. Miller WC, Mason JW. Abbreviated aerosol therapy for improved efficiency. J Aerosol Med 1998; 11(3):127–131.
13. Stenton SC, Dennis JH, Hendrick DJ. Occupational asthma due to ceftazidime. Eur J Respir Dis 1995; 8:1421–1423.
14. Alberts WM. Occupational asthma in the respiratory care workers. Respir Care 1993; 38(9):977–1004.
15. Noone PG, Regnis JA, Liu X, Brouwer KL, Robinson M, Edwards L, Knowles MR. Airway deposition and clearance and systemic pharmacokinetics of amiloride following aerosolization with an ultrasonic nebulizer to normal airways. Chest 1997; 112(5):1283–1290.
16. Ito K, Kikuchi S, Yamada M, Torii S, Yoshida M. Time course of drug concentrations in nebulizers and nebulized solutions. Arerugi 1992; 41(7):772–777 (in Japanese)
17. Takano H, Nakazawa M, Asai K, Itoh M. Performances of a new clinical nebulizer for drug administration based on the mesh-type ultrasonic atomization by elastic surface waves. J Aerosol Med 1999; 12(2):98.
18. Zierenberg B, Eicher J, Dunne S, Freund B. Boehringer Ingelheim Nebulizer BINEB, a new approach to inhalation therapy. In Respiratory Drug Delivery V. Buffalo Grove, IL: Interpharm Press, 1996:187–193.
19. Pavia D, Thomson ML, Clarke SW, Shannon HS. Effect of lung function and mode of inhalation on penetration of aerosol into the human lung. Thorax 1977; 32:194–197.
20. Whelan AM, Hahn NW. Optimizing drug delivery from metered-dose inhalers. DICP Ann Pharmacother 1991; 25:638–645.
21. Newman SP, Brown J, Steed KP, Reader SJ, Kladders H. Lung deposition of fenoterol and flunisolide using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest 1998; 113:957–963.
22. Newman SP, Steed KP, Reader SJ, Hooper G, Zierenberg B. Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J Pharm Sci 1996; 85:960–964.
23. Kunkel G, Magnussen H, Bergmann K-C, Juergens U, De May C, Freund E, Hinzmann R, Jahnel B. Cumulative dose response study comparing a new soft mist inhaler with a conventional MDI for delivery of fenoterol/ipratropium bromide combination in patients with asthma. Eur Respir J 1997; 10(suppl 25):104s.
24. Schuster G, Rubsamen R, Lloyd P, Lloyd G. The AERx aerosol delivery system. Pharm Res 1997; 14:354–357.
25. Schuster G, Farr S, Chipolla D, Wilbanks T, Rosell J, Lloyd P, Gonda I. Design and performance validation of highly efficient and reproducible compact aerosol delivery system AERx Respiratory Drug Delivery VI. Buffalo Grove, IL: Interpharm Press, 1998:83–90.
26. Stangl R, Lauangkhot N, Liening-Ewert R, Jahn D Characterising the functional model of a vibrating membrane nebulizer. Paper presented at the Aerosol Society, Dublin, 1999.
27. Ganan-Calvo AM, Barrero A. A Novel pneumatic technique to generate steady capillary microjets. J Aerosol Sci 1999; 30(1):117–125.
28. Clark AR, Gonda I, Newhouse MT. Towards meaningful laboratory tests for evaluation of pharmaceutical aerosols. J Aerosol Med 1998; 11(suppl 1):S1–S7.
29. Dennis JH, Pierron CA, Nerbrink O. Standards in assessing in vitro nebulizer performance. Eur Respir J. In press.
30. Draft European Nebuliser Standard. prEN13544 13544-1. Respiratory Therapy Equipment Part 1: Nebulizing Systems (available through all national European Standards bodies, e.g., in UK available through BSI ref BS 99/5662734DC).
31. Denyer J. Breathing patterns in adult patients. J Aerosol Med 1997; 10(1):99.
32. Stapleton KW, Finlay WH. Errors in characterizing nebulized particle size Distributions with cascade impactors. J Aerosol Med 1998; 11(Suppl 1):80–83.
33. Silkstone VL, Dennis JH, Chrystyn H. In-vivo/in-vitro correlation for nebulizers. In: Drug Delivery to the Lungs X. London: 1999.
34. Boe J, Dennis JH. European Respiratory Society nebulizer guidelines: technical aspects. Eur Respir Rev 2000; 73
35. Boe J, O’Driscoll R, Dennis JH. European Respiratory Society Nebulizer Guidelines: clinical aspects. Eur Respir Rev. In press.